Sort
23,748 grants matching “melanoma”
Suppression of Melanoma Initiation and Progression by NM23-H1
$361,343David M Kaetzel · University Of Maryland Baltimore · R01 · FY2014 · CA
Intracerebrally delivered EGFRvIII-targeted CARs for brain tumors
$361,290John H Sampson · Duke University · P50 · FY2017 · CA
The regulation of melanocyte stem cells by Wnt signaling
$361,238Mayumi Ito · New York University School Of Medicine · R01 · FY2013 · AR
Functional Analysis of Galectin-1 Ligands in Melanoma Progression
$361,144Charles J Dimitroff · Brigham And Women'S Hospital · R01 · FY2015 · CA
Targeted Combination Therapy for Melanoma
$361,118Meenhard Herlyn · Wistar Institute · P50 · FY2018 · CA
P38 MAPK is a molecular switch that controls the acquired resistance in adoptive cell therapy
$361,117Yong Lu · Methodist Hospital Research Institute · R37 · FY2023 · CA
Cell Biological Mechanisms of Melanoma Cell Motility In Vivo
$361,105Minna Roh · University Of Utah · R00 · FY2020 · CA
BRAFV600E and VEGFR2 synergize to trigger papillary thyroid cancer progression
$361,050Carmelo Nucera · Beth Israel Deaconess Medical Center · R01 · FY2017 · CA
BRAFV600E and VEGFR2 synergize to trigger papillary thyroid cancer progression
$361,050Carmelo Nucera · Beth Israel Deaconess Medical Center · R01 · FY2014 · CA
BRAFV600E and VEGFR2 synergize to trigger papillary thyroid cancer progression
$361,050Carmelo Nucera · Beth Israel Deaconess Medical Center · R01 · FY2018 · CA
BRAFV600E and VEGFR2 synergize to trigger papillary thyroid cancer progression
$361,050Carmelo Nucera · Beth Israel Deaconess Medical Center · R01 · FY2015 · CA
BRAFV600E and VEGFR2 synergize to trigger papillary thyroid cancer progression
$361,050Carmelo Nucera · Beth Israel Deaconess Medical Center · R01 · FY2016 · CA
Community Outreach and Engagement
$360,986Folakemi T Odedina · Mayo Clinic Rochester · P30 · FY2025 · CA
Mutant BRAF as a Therapeutic Target for Melanoma
$360,960Dorothee M Herlyn · Wistar Institute · P01 · FY2011 · CA
Innate immunity in dermal fibrosis and systemic sclerosis
$360,959Robert A Lafyatis · Boston University Medical Campus · R01 · FY2014 · AR
Role of Perivascular Mesenchymal Stem Cells (pMSCs) in the Bone Marrow Niche and the Extracellular Matrix in the Control of Skeletal Metastasis
$360,922Rodrigo Alfonso Somoza · Case Western Reserve University · R01 · FY2023 · CA
NIR Imaging of Sentinel Nodes in Lung Cancer: Finding Micrometastases
$360,905Yolonda L Colson · Brigham And Women'S Hospital · R01 · FY2010 · CA
Identification and characterization of cancer cell states by novel computational and experimental technologies - Resubmission - 1
$360,869Itai Yanai · New York University School Of Medicine · U01 · FY2025 · CA
Mitf: A Master Gene for Melanocyte Development
$360,866David E Fisher · Massachusetts General Hospital · R01 · FY2010 · AR
NIR Imaging of Sentinel Nodes in Lung Cancer: Finding Micrometastases
$360,853Yolonda L Colson · Brigham And Women'S Hospital · R01 · FY2009 · CA
CRYPTIC DOMAINS OF COLLAGEN IV IN TUMOR GROWTH
$360,814New York University School Of Medicine · R01 · FY2004 · CA
Defining Transcriptional Regulators of Melanoma Initiation using Zebrafish
$360,751Charles Kore Kaufman · Washington University · R01 · FY2021 · CA
Defining Transcriptional Regulators of Melanoma Initiation using Zebrafish
$360,751Charles Kore Kaufman · Washington University · R01 · FY2022 · CA
Defining Transcriptional Regulators of Melanoma Initiation using Zebrafish
$360,751Charles Kore Kaufman · Washington University · R01 · FY2020 · CA
Cohort Study of Genetic Susceptibility to Cutaneous Malignant Melanoma
$360,731Jiali Han · Brigham And Women'S Hospital · R01 · FY2009 · CA